NASDAQ:SYNH - Syneos Health Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$49.85 +0.60 (+1.22 %)
(As of 09/25/2018 04:00 PM ET)
Previous Close$49.25
Today's Range$48.90 - $50.35
52-Week Range$31.10 - $59.45
Volume602,900 shs
Average Volume840,799 shs
Market Capitalization$5.05 billion
P/E Ratio25.70
Dividend YieldN/A
Beta0.81
Syneos Health logoSyneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic collaboration with Elligo Health Research. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.

Receive SYNH News and Ratings via Email

Sign-up to receive the latest news and ratings for SYNH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYNH
CUSIPN/A
Phone919-876-9300

Debt

Debt-to-Equity Ratio1.01
Current Ratio1.04
Quick Ratio1.04

Price-To-Earnings

Trailing P/E Ratio25.70
Forward P/E Ratio20.60
P/E Growth1.16

Sales & Book Value

Annual Sales$2.67 billion
Price / Sales1.92
Cash Flow$3.8376 per share
Price / Cash12.99
Book Value$28.97 per share
Price / Book1.72

Profitability

EPS (Most Recent Fiscal Year)$1.94
Net Income$-138,460,000.00
Net Margins-4.32%
Return on Equity7.80%
Return on Assets3.17%

Miscellaneous

Employees21,000
Outstanding Shares102,880,000
Market Cap$5.05 billion

Syneos Health (NASDAQ:SYNH) Frequently Asked Questions

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

How were Syneos Health's earnings last quarter?

Syneos Health Inc (NASDAQ:SYNH) issued its quarterly earnings results on Thursday, August, 2nd. The company reported $0.62 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.61 by $0.01. The business earned $1.07 billion during the quarter, compared to the consensus estimate of $1.09 billion. Syneos Health had a positive return on equity of 7.80% and a negative net margin of 4.32%. The firm's revenue for the quarter was up 315.5% compared to the same quarter last year. View Syneos Health's Earnings History.

When is Syneos Health's next earnings date?

Syneos Health is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Syneos Health.

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health issued an update on its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share guidance of $2.84-3.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.70.

What price target have analysts set for SYNH?

9 Wall Street analysts have issued 12 month target prices for Syneos Health's stock. Their forecasts range from $50.00 to $60.00. On average, they expect Syneos Health's share price to reach $53.50 in the next year. This suggests a possible upside of 7.3% from the stock's current price. View Analyst Price Targets for Syneos Health.

What is the consensus analysts' recommendation for Syneos Health?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.

Who are some of Syneos Health's key competitors?

Who are Syneos Health's key executives?

Syneos Health's management team includes the folowing people:
  • Mr. Alistair MacDonald, CEO & Director (Age 48)
  • Dr. Michael Gibertini, Pres of Clinical Devel. for Therapeutic Bus. Units (Age 60)
  • Mr. Jason M. Meggs, CFO & Principal Accounting Officer (Age 42)
  • Dr. Judith Ng-Cashin, Chief Scientific Officer
  • Ms. Rachel Stahler, Chief Information Officer (Age 42)

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.08%), Dimensional Fund Advisors LP (1.62%), Cooke & Bieler LP (1.28%), Northern Trust Corp (1.01%), Redmile Group LLC (0.95%) and Boston Partners (0.71%). Company insiders that own Syneos Health stock include Alistair Macdonald, Christopher L Gaenzle, D Jamie Macdonald, Gregory S Rush, H Lee Equity Fund Vi Thomas and Robert W Breckon. View Institutional Ownership Trends for Syneos Health.

Which institutional investors are selling Syneos Health stock?

SYNH stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Jennison Associates LLC, Clearline Capital LP, Sapience Investments LLC, Thompson Siegel & Walmsley LLC, Schroder Investment Management Group, Schroder Investment Management Group and Dimensional Fund Advisors LP. Company insiders that have sold Syneos Health company stock in the last year include Christopher L Gaenzle and H Lee Equity Fund Vi Thomas. View Insider Buying and Selling for Syneos Health.

Which institutional investors are buying Syneos Health stock?

SYNH stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Mesirow Financial Investment Management Equity Management, BlackRock Inc., Bank of America Corp DE, Beach Point Capital Management LP, Natixis, SG Americas Securities LLC and Macquarie Group Ltd.. View Insider Buying and Selling for Syneos Health.

How do I buy shares of Syneos Health?

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $49.85.

How big of a company is Syneos Health?

Syneos Health has a market capitalization of $5.05 billion and generates $2.67 billion in revenue each year. The company earns $-138,460,000.00 in net income (profit) each year or $1.94 on an earnings per share basis. Syneos Health employs 21,000 workers across the globe.

What is Syneos Health's official website?

The official website for Syneos Health is http://www.incresearch.com.

How can I contact Syneos Health?

Syneos Health's mailing address is 3201 Beechleaf Court Suite 600, Raleigh NC, 27604. The company can be reached via phone at 919-876-9300 or via email at [email protected]


MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  372 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  651
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel